Overview

Generalized Anxiety Disorder Adjunct Study

Status:
Completed
Trial end date:
2008-09-01
Target enrollment:
Participant gender:
Summary
This study is being carried out to see if extended release quetiapine fumarate (Seroquel®XL) when added to standard selective serotonin reuptake inhibitor (SSRI) / serotonin-norepinephrine reuptake inhibitor (SNRI) therapy is effective and safe for the treatment of Generalized Anxiety Disorder in patients with partial or no response to SSRI/SNRI alone or in combination with a benzodiazepine, and if so, how it compares with placebo
Phase:
Phase 3
Details
Lead Sponsor:
AstraZeneca
Treatments:
Quetiapine Fumarate